Posted on

CareDx Committed to Delivering Clinical Innovation to the Transplant Patient and Physician Community

Loading

NOVEMBER 11, 2022

CareDx Leads Scientific Evidence with Over 100 Peer-Reviewed Publications Supporting the Clinical Use of AlloSure and AlloMap for Organ Transplant Patients

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the five-year anniversary of AlloSure®, the groundbreaking, non-invasive donor-derived cell-free DNA (dd-cfDNA) surveillance solution used to measure allograft injury in solid organ transplant recipients. AlloSure along with AlloMap® represent disruptive innovations in the field of solid organ transplant. Read the full press release on CareDx.com.

Loading
Posted on

CareDx Demonstrates Power of AlloSure and Digital Health Transplant Solutions at American Society of Nephrology Kidney Week

Loading

NOVEMBER, 02, 2022

CareDx Showcases Latest Innovations in Pre- and Post-Transplant Patient Care

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will be sharing the latest data on AlloSure® Kidney and its patient-centered digital health solutions at the American Society of Nephrology (ASN) Kidney Week 2022 meeting being held November 3 – 6 in Orlando, Florida.
Read the complete press release on CareDx.com.

Loading
Posted on

Independent Longitudinal Study Finds CareDx’s AlloSure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients

Loading

NOVEMBER, 01, 2022

First Pediatric Study to Evaluate Use of AlloSure dd-cfDNA as Biomarker for Allograft BK Infection

Findings Add to Growing Body of Evidence Showing Clinical Value of AlloSure for Surveillance in Pediatric Kidney Transplant Patients

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the results of a new study published in the Clinical Journal of the American Society of Nephrology (CJASN)1 showing that CareDx’s AlloSure® Kidney donor-derived cell-free DNA (dd-cfDNA) solution identifies early signs of allograft rejection and BK virus infection in pediatric kidney transplant patients.
Read the complete press release on CareDx.com.

Loading
Posted on

CareDx to Host Symposium Covering Innovation in Multimodal Surveillance Including AiCAV for Post-Cardiac Transplant Care

Loading

CareDx to Host Symposium Covering Innovation in Multimodal Surveillance Including AiCAV for Post-Cardiac Transplant Care

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will host a symposium to describe the latest innovations in post-cardiac transplant care at the HFSA (Heart Failure Society of America) Annual Scientific Meeting 2022 taking place in Washington, D.C., September 30 – October 3.

“We look forward to HFSA where we will share more on our AI Heart Platform with AiCAV™, a new offering in development that will help to inform clinicians in their assessment of cardiac allograft vasculopathy risk,” said Reg Seeto, CEO and President of CareDx. “For over two decades, CareDx has been leading innovation to improve outcomes for transplant patients and we are extremely proud to extend this leadership with AiKidney™ and AiCAV.” Read the full press release on CareDx.com.

Loading
Posted on

Transplant Patients Experience Less Pain and Fewer Adverse Events with CareDx Non-Invasive Testing Solutions

Loading

Study Reaffirms Benefits of AlloMap, the Industry’s Only Gene-Expression Profiling Blood Test, for Heart Transplant Rejection Surveillance

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a new peer-reviewed publication showing that AlloMap®, the industry’s only gene-expression profiling (GEP) blood test to non-invasively assess graft rejection by monitoring immune quiescence in heart transplant patients,1 resulted in less pain and fewer adverse events compared to heart biopsy.2 The study also highlights that the associated AlloMap blood test draw can be performed in the patient’s home to help reduce the risk of exposure to infection. Read the complete press release on CareDx.com.

Loading
Posted on

CareDx Congratulates Board Member Dr. Grace Colón for Being Named Healthcare Innovator on Top 50 Most Powerful Latinas List

Loading

The Association of Latino Professionals For America Recognizes the Most Powerful Latinas in Business, Technology, Healthcare, and Non-Profit Sectors

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Dr. Grace Colón, a member of its Board of Directors, has been named on the 2022 Most Powerful Latinas list by The Association of Latino Professionals For America (ALPFA).

“We congratulate Dr. Colón for being named a healthcare innovator by ALPFA and for her significant contribution in driving innovation to improve patient care,” said Michael D. Goldberg, Chairman of the Board, CareDx. “As Chair of CareDx’s Science and Technology Committee she has played an invaluable role in helping shape the company’s innovation agenda focused on improving the transplant patient journey.”
Read the complete press release on CareDx.com.

Loading
Posted on

CareDx Celebrates 1 Million Organ Transplants and 100,000 Patient Milestone

Loading

One out of Ten Patients Served by CareDx

Signals Broad Uptake of Company’s Non-Invasive Testing Services for Heart, Kidney, and Lung Transplant Patients

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has served its 100,000th transplant patient, representing one out of ten patients transplanted in the U.S. This milestone demonstrates strong clinical adoption of molecular surveillance for transplant patients and showcases AlloMap® and AlloSure® as leading tools which are becoming firmly embedded in post-transplant patient care. Read the press release on CareDx.com.

Loading
Posted on

CareDx Demonstrates Global Leadership at 29th International Congress of The Transplantation Society

Loading

Over 25 Abstracts Highlight Value of AlloSure and AlloSeq cfDNA

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its leading participation in the 29th International Congress of The Transplantation Society (TTS 2022) taking place September 10-14 in Buenos Aires, Argentina.

Transplant physicians will present data from over 25 abstracts demonstrating the value of AlloSure® donor-derived cell-free DNA (dd-cfDNA) and AlloSeq cfDNA in clinical practice, and emerging trends and innovation in transplantation, including artificial intelligence and the potential use of CareDx’s molecular testing services for xenotransplantation surveillance. Read the complete press release on CareDx.com.

Loading
Posted on

CareDx and MOTTEP Co-Host Health Equity Summit

Loading

Panelists Offer Different Perspectives to Address Health Disparities in Organ Transplantation

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will co-host, along with MOTTEP (Minority Organ Tissue Transplantation Education Program), a panel discussion, “Tackling Health Equity in Organ Transplantation,” on August 18, 2022, 10:00-11:00am PST (1:00–2:00pm EST). The event is timed in recognition of National Minority Donor Awareness Month.

The event will bring greater awareness of health disparities in organ transplantation and discuss actionable solutions to address them. The event will be co-hosted by Reg Seeto, CEO and President of CareDx, and Dr. Clive Callender, Founder of MOTTEP.
Read the full press release on CareDx.com

Loading
Posted on

CareDx Unveils New Patient-Centered Medication Management Features on AlloCare Mobile Health App

Loading

Integration of MedActionPlan PRO Facilitates Patient-Clinician Interaction to Improve Medication Adherence

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that its AlloCare® mobile health app features expanded medication adherence and patient-provider communication capabilities resulting from the successful integration of MedActionPlan®, an acquisition made last year. Read the full press release on CareDx.com.

Loading